An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity

被引：0
|
作者：
Lian-sheng Cheng
Min Zhu
Yan Gao
Wen-ting Liu
Wu Yin
Pengfei Zhou
Zhongliang Zhu
Liwen Niu
Xiaoli Zeng
Dayan Zhang
Qing Fang
Fengrong Wang
Qun Zhao
Yan Zhang
Guodong Shen
机构：
[1] University of Science and Technology of China,Department of Geriatrics, The First Affiliated Hospital of University of Science and Technology of China, Gerontology Institute of Anhui Province, Division of Life Sciences and Medicine
[2] Hefei HankeMab Biotechnology Limited,Anhui Province Key Laboratory of Gene Engineering Pharmaceutical, Biomedicine Technology Innovation Center of Hefei
[3] Anhui Provincial Key Laboratory of Tumor Immunotherapy and Nutrition Therapy,School of Life Sciences, Division of Life Sciences and Medicine
[4] Anhui Anke Biotechnology (Group) Co.,School of Health Service Management
[5] Ltd.,undefined
[6] University of Science and Technology of China,undefined
[7] Anhui Medical University,undefined
来源：
Cellular & Molecular Biology Letters | / 28卷
关键词：
Colorectal cancer; Cancer immunotherapy; 4-1BB/CD137; PD-1/PD-L1; Immune checkpoint inhibitor; Antitumor immunity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] KEY PHARMACOKINETIC AND PHARMACODYNAMIC PARAMETERS THAT CORRELATE WITH THE ANTI-TUMOR ACTIVITY OF A BISPECIFIC PD-L1 CONDITIONAL 4-1BB AGONIST
    Kinkead, Heather
    Macedo, Chelsie
    Sanabria, Angelica
    Cyprus, Garrett
    Pandit, Rajay
    Kalabus, James
    Becklund, Bryan
    Sulzmaier, Florian
    Timmer, John
    Deveraux, Quinn
    Eckelman, Brendan
    Heidt, Analeah
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A12 - A12
  • [22] Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
    Li, Tianye
    Wang, Xinrun
    Niu, Mengke
    Wang, Mingli
    Zhou, Jianwei
    Wu, Kongming
    Yi, Ming
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [23] Fc-silenced bispecific antibodies targeting PD-L1 and 4-1BB combine checkpoint blockade and T-cell co-stimulation to promote anti-tumor activity
    Muik, Alexander
    Altintas, Isil
    Gieseke, Friederike
    Salcedo, Theodora
    Burm, Saskia
    Diken, Mustafa
    Grunwitz, Christian
    Schuurhuis, Danita
    Kreiter, Sebastian
    Satijn, David
    Tureci, Ozlem
    Breij, Esther
    Sahin, Ugur
    Jure-Kunkel, Maria
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [24] A NOVEL ANTI-MSLN X 4-1BB BISPECIFIC ANTIBODY WITH FC EFFECT FUNCTION AUGMENTS THE ANTITUMOR EFFICACY
    Cheng, Liansheng
    Zhang, Dayan
    Zhang, Dayan
    Wu, Lingling
    Zhou, Weiming
    Zeng, Xiaoli
    Dai, Xuejing
    Liu, Wenting
    Zhao, Qun
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1259 - A1259
  • [25] An Fc-competent bispecific antibody targeting PD-L1 and TIGIT induces strong immune responses and potent anti-tumor efficacy.
    Dai, Shuang
    Huang, Weifeng
    Yuan, Zhijun
    Peng, Shaogang
    Si, Jiayi
    Wang, Chao
    Yan, Yao
    Miao, Xiaoniu
    Xu, Yingda
    Sun, Joanne
    Liu, Xiaolin
    Tsun, Andy
    Zhai, Tianhang
    CANCER RESEARCH, 2022, 82 (12)
  • [26] PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer
    Stein, Alexander
    Simnica, Donjete
    Schultheiss, Christoph
    Scholz, Rebekka
    Tintelnot, Joseph
    Goekkurt, Eray
    von Wenserski, Lisa
    Willscher, Edith
    Paschold, Lisa
    Sauer, Markus
    Lorenzen, Sylvie
    Riera-Knorrenschild, Jorge
    Depenbusch, Reinhard
    Ettrich, Thomas J.
    Doerfel, Steffen
    Al-Batran, Salah-Eddin
    Karthaus, Meinolf
    Pelzer, Uwe
    Waberer, Lisa
    Hinke, Axel
    Bauer, Marcus
    Massa, Chiara
    Seliger, Barbara
    Wickenhauser, Claudia
    Bokemeyer, Carsten
    Hegewisch-Becker, Susanna
    Binder, Mascha
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (07)
  • [27] Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
    Muik, Alexander
    Garralda, Elena
    Altintas, Isil
    Gieseke, Friederike
    Geva, Ravit
    Ben-Ami, Eytan
    Maurice-Dror, Corinne
    Calvo, Emiliano
    LoRusso, Patricia M.
    Alonso, Guzman
    Rodriguez-Ruiz, Maria E.
    Schoedel, Kristina B.
    Blum, Jordan M.
    Sanger, Bianca
    Salcedo, Theodora W.
    Burm, Saskia M.
    Stanganello, Eliana
    Verzijl, Dennis
    Vascotto, Fulvia
    Sette, Angelica
    Quinkhardt, Juliane
    Plantinga, Theo S.
    Toker, Aras
    van den Brink, Edward N.
    Fereshteh, Mark
    Diken, Mustafa
    Satijn, David
    Kreiter, Sebastian
    Breij, Esther C. W.
    Bajaj, Gaurav
    Lagkadinou, Eleni
    Sasser, Kate
    Tureci, Ozlem
    Forssmann, Ulf
    Ahmadi, Tahamtan
    Sahin, Ugur
    Jure-Kunkel, Maria
    Melero, Ignacio
    CANCER DISCOVERY, 2022, 12 (05) : 1248 - 1265
  • [28] Converting Tumoral PD-L1 into a 4-1BB Agonist for Safer and More Effective Cancer Immunotherapy
    Li, Zihai
    Azar, Joseph H.
    Rubinstein, Mark P.
    CANCER DISCOVERY, 2022, 12 (05) : 1184 - 1186
  • [29] Development of Plant-Derived Bispecific Monoclonal Antibody Targeting PD-L1 and CTLA-4 against Mouse Colorectal Cancer
    Bulaon, Christine Joy I.
    Khorattanakulchai, Narach
    Rattanapisit, Kaewta
    Sun, Hongyan
    Pisuttinusart, Nuttapat
    Phoolcharoen, Waranyoo
    PLANTA MEDICA, 2024, 90 (04) : 305 - 315
  • [30] A phase 1, dose escalation/dose-expansion study of QLF31907, a bispecific antibody (BsAb) targeting PD-L1 and 4-1BB, in patients with advanced solid tumors and lymphoma
    Lin, Tongyu
    Liu, Bin
    Pu, Xingxiang
    Wu, Lin
    Du, Xiaobo
    Mo, Ning
    Song, Zhengbo
    Zhou, Liwei
    Duan, Xianlin
    Zhu, Yanan
    Kang, Xiaoyan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345